Shares of Pharmaceutical company Royalty Pharma climbed 8.3% this afternoon. Here are some quick facts to get you started if you are interested in the stock:
-
Royalty Pharma has logged a -28.4% 52 week change, compared to 18.7% for the S&P 500
-
RPRX has an average analyst rating of buy and is -35.56% away from its mean target price of $46.57 per share
-
Its trailing earnings per share (EPS) is $0.39, which brings its trailing Price to Earnings (P/E) ratio to 76.9. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $3.71 and its forward P/E ratio is 8.1
-
The company has a Price to Book (P/B) ratio of 2.18 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 13.5, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
RPRX has reported YOY quarterly earnings growth of -50.7% and gross profit margins of 0.6%
-
The company's free cash flow for the last fiscal year was $2.79 Billion and the average free cash flow growth rate is 11.2%
-
Royalty Pharma's revenues have an average growth rate of 1.8% with operating expenses growing at 40.6%. The company's current operating margins stand at 17.1%